Senti Biosciences Inc
SNTI1.350USD
-0.040-2.88%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
35.32MMarket Cap
LossP/E TTM
More Details of Senti Biosciences Inc Company
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
Company Info
Ticker SymbolSNTI
Company nameSenti Biosciences Inc
IPO dateMay 26, 2021
CEODr. Timothy (Tim) Lu, M.D., Ph.D.
Number of employees34
Security typeOrdinary Share
Fiscal year-endMay 26
Address2 Corporate Drive, First Floor
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone16502392030
Websitehttps://www.sentibio.com/
Ticker SymbolSNTI
IPO dateMay 26, 2021
CEODr. Timothy (Tim) Lu, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Mr. Bryan Baum
Mr. Bryan Baum
Director
Director
--
--
Ms. Frances D. Schulz
Ms. Frances D. Schulz
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Donald Tang
Mr. Donald Tang
Director
Director
--
--
Mr. Jay Cross
Mr. Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. Feng Hsiung
Mr. Feng Hsiung
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Mr. Bryan Baum
Mr. Bryan Baum
Director
Director
--
--
Ms. Frances D. Schulz
Ms. Frances D. Schulz
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Celadon Partners SPV 24
37.37%
New Enterprise Associates (NEA)
14.43%
Bayer HealthCare LLC
10.74%
PharmaEssentia Corp.
8.07%
Armistice Capital LLC
3.41%
Other
25.97%
Shareholders
Shareholders
Proportion
Celadon Partners SPV 24
37.37%
New Enterprise Associates (NEA)
14.43%
Bayer HealthCare LLC
10.74%
PharmaEssentia Corp.
8.07%
Armistice Capital LLC
3.41%
Other
25.97%
Shareholder Types
Shareholders
Proportion
Corporation
56.18%
Venture Capital
14.43%
Hedge Fund
6.81%
Investment Advisor
3.90%
Individual Investor
0.85%
Investment Advisor/Hedge Fund
0.61%
Other
17.21%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
59
22.40M
85.87%
+17.02M
2025Q1
61
32.06M
123.04%
+28.81M
2024Q4
55
2.74M
57.01%
+442.53K
2024Q3
56
2.03M
44.31%
-591.63K
2024Q2
59
2.00M
43.68%
-736.88K
2024Q1
91
2.11M
47.03%
-1.57M
2023Q4
97
2.11M
47.62%
-1.61M
2023Q3
101
2.43M
55.03%
-1.49M
2023Q2
105
2.45M
55.45%
-1.56M
2023Q1
104
2.49M
56.56%
-1.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Celadon Partners SPV 24
9.78M
37.49%
+9.78M
--
Mar 18, 2025
New Enterprise Associates (NEA)
3.78M
14.48%
+3.33M
+753.02%
Mar 31, 2025
Bayer HealthCare LLC
2.81M
10.77%
+2.22M
+377.99%
Mar 10, 2025
PharmaEssentia Corp.
2.11M
8.09%
--
--
Apr 28, 2025
Armistice Capital LLC
1.44M
5.52%
+903.80K
+168.62%
Mar 31, 2025
Nantahala Capital Management, LLC
888.00K
3.4%
+378.72K
+74.36%
Mar 31, 2025
Heights Capital Management, Inc.
750.00K
2.88%
+750.00K
--
Mar 31, 2025
The Vanguard Group, Inc.
154.14K
0.59%
+56.67K
+58.14%
Mar 31, 2025
8VC GP I, LLC
253.75K
0.97%
--
--
Mar 31, 2025
Lu (Timothy K M.D., Ph.D.)
161.63K
0.62%
--
--
Apr 28, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Date
Type
Ratio
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
